INFOS !
  • NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

More about accessibility

Trouble using our website?
Contact us

Text logo ERN-EYE Tools
CPMS REDgistry Elearning Members area
Accessibility

RECOVER

In this page

Clinical Trial

NCT02521311 Recruiting, Active
RECOVER

This trial does use Clemastine fumarat as a remyelinating agent targeting themuscarinic receptor on oligodendrocytes around the optic nerve.

Phase 2
Interventional

Disease

Disease type

Hereditary retinal disease

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

28/02/2017

Closing date

31/08/2024

Inclusion criteria :

More

Exclusion criteria :

More

Funding

other

Members involved

Main investigators

Dr Axel PETZOLD

Netherlands

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

Others investigators

ERN EYE member investigating site

HCP : Principal investigators

HCP : Others investigators

More